scispace - formally typeset
Y

Yingjiang Ye

Researcher at Peking University

Publications -  229
Citations -  4721

Yingjiang Ye is an academic researcher from Peking University. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 29, co-authored 192 publications receiving 3047 citations. Previous affiliations of Yingjiang Ye include Peking Union Medical College & Dalian Medical University.

Papers
More filters
Journal ArticleDOI

Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.

TL;DR: An integrated RNA-sequencing approach demonstrates that CXCL13+ TH1-like cells are preferentially enriched in microsatellite-instable tumours from patients with colorectal cancer, and IGFLR1 is identified as a co-stimulatory molecule.
Journal ArticleDOI

Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer.

TL;DR: This comprehensive analysis of key myeloid subsets in human and mouse identifies critical cellular interactions regulating tumor immunity and defines mechanisms underlying myeloids-targeted immunotherapies currently undergoing clinical testing.
Journal ArticleDOI

Impact of postoperative omega-3 fatty acid-supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients

TL;DR: Postoperative supplementation of omega-3 fatty acids may have a favorable effect on the outcomes in colorectal cancer patients undergoing radical resection by lowering the magnitude of inflammatory responses and modulating the immune response.
Journal ArticleDOI

Safety, quality and effect of complete mesocolic excision vs non‐complete mesocolic excision in patients with colon cancer: a systemic review and meta‐analysis

TL;DR: A meta‐analysis was performed to compare the safety, quality and effect of CME with non‐complete mesocolic excision (NCME) in patients with colon cancer.
Journal ArticleDOI

[Corrigendum] MicroRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer.

TL;DR: It is suggested that miR-320a may be a novel therapeutic candidate for the treatment of colorectal cancer and useful for identifying CRC patients that are at an elevated risk for developing liver metastasis.